8-K: Allurion Technologies Secures $2.5 Million Private Placement to Extend Runway Through Early 2026

Allurion Technologies announces a $2.5 million private placement with RTW Investments, LP, to extend its financial runway and support its 2025 strategic plan.

Summary

• Allurion Technologies, Inc. has entered into a subscription agreement with funds affiliated with RTW Investments, LP for a private placement of 841,751 shares of common stock at $2.97 per share.
• The private placement is expected to generate gross proceeds of $2.5 million, extending the company's financial runway through early 2026.
• The agreement includes an option for Allurion to secure up to an additional $10 million in subsequent tranches.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• Allurion also announced preliminary unaudited revenue for the fourth quarter of 2024 is expected to be approximately $5.6 million and full year revenue to be approximately $32 million, in line with previously issued guidance.
• Procedure volume growth for the full year, excluding France, is expected to be approximately 4%, higher than previously issued guidance.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company secured funding to extend its runway and preliminary results are in line with expectations. However, the company still faces risks and challenges in a competitive market.

Positives

• The private placement provides Allurion with additional capital to execute its 2025 plan.
• The extended financial runway through early 2026 offers stability and time for strategic initiatives.
• The option for an additional $10 million in funding provides flexibility for future growth opportunities.
• Preliminary revenue figures are in line with previous guidance.
• Procedure volume growth exceeded previous guidance.

Risks

• The preliminary financial results are unaudited and subject to change.
• The company's ability to achieve its 2025 plan depends on various factors, including FDA approval and commercialization success.
• The company faces risks related to regulatory approvals, clinical trial outcomes, market competition, intellectual property, and economic conditions.
• The company's future performance is subject to various risks and uncertainties described in its SEC filings.

Future Outlook

Allurion plans to scale its new commercial strategy, advance the Allurion Balloon through the FDA approval process, set the company up for a profitable 2026, expand its digital business lines, and resume commercialization in France.

Management Comments

• Dr. Shantanu Gaur, Founder and Chief Executive Officer, stated that the company is pleased with the preliminary unaudited results from the fourth quarter.
• Dr. Gaur believes the private placement from RTW provides the runway needed to execute the 2025 plan and that 2025 will be a pivotal year for Allurion.

Industry Context

This announcement comes as Allurion navigates the competitive weight-loss market, including the rise of GLP-1 drugs, and seeks to expand its digital business and global reach.

Comparison to Industry Standards

• It is difficult to compare Allurion's results directly to industry standards without knowing the specific growth rates and financial metrics of its direct competitors in the gastric balloon market.
• Companies like Apollo Endosurgery (now part of Boston Scientific) and ReShape Lifesciences are key players in the bariatric surgery and weight loss device market.
• Allurion's focus on a swallowable, procedure-less gastric balloon differentiates it from traditional surgical options and other device-based approaches.
• The 4% procedure volume growth, excluding France, suggests moderate growth in a competitive market, but further analysis would be needed to compare this to the growth rates of similar companies.

Stakeholder Impact

• Shareholders: The private placement dilutes existing shareholders but provides the company with necessary capital.
• Employees: The extended financial runway provides job security and supports the company's strategic initiatives.
• Customers: The company's ability to continue operations and innovate in the weight-loss market benefits customers.
• Suppliers: The company's financial stability ensures continued business relationships with suppliers.
• Creditors: The company's improved financial position reduces credit risk for creditors.

Next Steps

• The private placement is expected to close on or about January 15, 2025, subject to customary closing conditions.
• The company will file a resale registration statement with the SEC within 45 days after the Closing Date.
• The company must use commercially reasonable efforts to have such registration statement declared effective by the SEC as soon as practicable.

Key Dates